Column
- HOME
- Column
You can view the research column published every month by SMC Laboratories.
2025.02.02
Preclinical data in NASH Mouse Model_β-glucans
Today’s topic is Effective and Safe Nutritional Supplements for NASH Management. I am writing you to introduce a study published by our client, GN Corporation. Title: “Two unique biological response-modifier glucans beneficially regulating gut microbiota and faecal metabolome in a non-alcoholic steatohepatitis animal model, with potential applications in human health and disease“. KEYWORD：β-glucans,…
2025.02.02
The STAM model as a model for hepatocellular carcinoma
We would like to introduce today a NASH-HCC model from SMC Laboratories (“STAMTM mice”) for your oncology R&D projects. The model has the following features compared with other HCC models. STAM model; – shows prompt (by 20 wks of age) and definite (nearly 100%) disease development to HCC – is non-genetic, NASH-associated cancer model…
2025.02.02
Research article published in Cells
We would like to introduce a new publication using the STAM™ model presented by our client NeuroVive in Cells. NeuroVive Title: “Evaluation of NV556, a Novel Cyclophilin Inhibitor, as a Potential Antifibrotic Compound for Liver Fibrosis” This paper analyzes the anti-fibrotic effect of NV556 in vivo. NV556 is an inhibitor of Cyclophilin, which…
2025.02.02
HCC model STAM in review paper [Liu et. al Hepatoma Research 2020;6:7]
STAM™ was originally developed as a NASH model, but with a 100% incidence of HCC as early as 20 weeks, it is also an excellent platform for oncology research and therapeutic development. A recently published review article by Liu et al. in Hepatoma Research overviews currently available murine models for HCC, and outlined the following…
2025.02.02
Translational relevance in STAM (NASH-HCC)
One factor that must be considered when selecting models for pre-clinical research is translatability. As of January 2020, 15 compounds tested in the STAM™ model have progressed to clinical trials. One such compound is Pegbelfermin, being developed in Phase 2 trials by Bristol-Meyers Squibb. The results of trials using Pegbelfermin have shown an improvement…
2025.02.02
Update on the clinical relevance of STAM model
One of our clients FDA-National Center for Toxicological Research (NCTR) has published the results of a study using STAMTM model in Toxicological Sciences. Title: “Gene Expression and DNA Methylation Alterations in the Glycine N-Methyltransferase Gene in Diet-Induced Nonalcoholic Fatty Liver Disease-Associated Carcinogenesis” Utilizing two NAFLD-HCC models (STAMTM and Diamond), this paper reports that Gnmt…
2025.02.02
One of our clients published preclinical data on NASH-fibrosis on Biochemistry
We announced that a study in the STAM™ mouse model of NASH performed by SMC Laboratories Inc. has been published in Biochemistry by University of Nebraska.: Title: “A Panel of Protein Kinase Chemosensors Distinguishes Different Types of Fatty Liver Disease” This study reported that a significant increase in MK2 (MAPKAPK2) activity in NAFLD (6…
2025.02.02
Update on the clinical relevance of STAM model
We announced that Dr. Karin’s group has presented the results of a study using STAM TM model in PNAS. Title: “Integrative genomic analysis of mouse and human hepatocellular carcinoma” The authors have demonstrated that STAM TM model is the only mouse model that closely recapitulated the molecular characteristics of human HCC. Please let me…
2025.02.02
One of our clients published preclinical data on NASH-fibrosis on Hepatology Communications
We announced that a study in the STAM™ mouse model of NASH performed by SMC Laboratories Inc. has been published in Hepatology Communications by Genomics Institute of the Novartis Research Foundation.: Title: “Tropifexor-Mediated Abrogation of Steatohepatitis and Fibrosis is Associated with the Antioxidative Gene Expression Profile in Rodents” Tropifexor, a novel nonbile acid FXR…
2025.02.02
One of our clients published preclinical data on NASH-fibrosis on International Journal of Gastroenterology
We announced that a study in the STAM™ mouse model of NASH performed by SMC Laboratories Inc. has been published in International Journal of Gastroenterology by Enanta Pharmaceuticals, Inc.: Title: “Characterization of EDP-305, a Highly Potent and Selective Farnesoid X Receptor Agonist, for the Treatment of Non-alcoholic Steatohepatitis” EDP-305, selective and potent FXR agonist,…
We can help you advance your research.